Overview of Газоспазам

Quick Facts

Property	Description
Active ingredient	Simeticone (Simethicone)
Form	Oral preparations (Capsules, suspensions, drops)
Pharmacological class	Antiflatulent / Miscellaneous GI Agent
General purpose	Symptomatic relief of gas-related discomfort
Origin	Synthetic silicone compound

Classification and Identity: What Type of Medicine is Газоспазам?

Газоспазам is a medicinal product defined by its active substance, Simethicone (Simeticone, INN), which functions primarily as an antiflatulent, a pharmacological class specialized for the management of symptoms arising from excessive gas in the digestive tract and categorized as a Miscellaneous GI Agent. Simethicone is a synthetic substance, a chemically inert silicone compound derived from siloxane polymers and silica gel, which is entirely non-systemic, meaning it acts locally within the gastrointestinal tract and is not absorbed into the bloodstream.

Composition and Physical Presentation

The active component, Simethicone, acts as a non-systemic surfactant, a crucial chemical characteristic that confirms its inert behavior within the gut. This compound functions by reducing the surface tension of gas bubbles in the gastrointestinal tract, leading to their collapse and easier expulsion. The compound is formulated for oral administration and is usually available as a single-ingredient medicine, though some presentations may be combined with antacids. Газоспазам is differentiated by its focus on multiple dosage form types, including liquid-filled capsules, oral suspensions (drops), and chewable tablets, ensuring suitability for a broad range of patients.

Core Function: What is the General Purpose of Antiflatulents?

The general purpose of Газоспазам is to provide focused, symptomatic relief from the unpleasant manifestations of excessive gas, notably abdominal bloating, pressure, and a feeling of fullness. Its functional principle is strictly physical: the Simethicone compound reduces the surface tension of the numerous small, stable foam bubbles trapped in the intestinal contents. This action promotes the coalescence of these bubbles into larger pockets of free gas, which facilitates the body's natural expulsion process, thereby alleviating the distension and discomfort. This mechanism is clinically recognized for its efficiency in treating gas and bloating symptoms.

What side effects are possible with Газоспазам?

Possible Side Effects and Safety Information

Gasospazam is a combination product containing alverine citrate (an antispasmodic) and simethicone (an antiflatulent). While generally well-tolerated, all medicines carry a risk of side effects.

Common and Less Common Side Effects

Side effects are often mild and temporary. The simethicone component is minimally absorbed into the bloodstream, limiting systemic effects. The following table summarizes potential side effects, primarily associated with alverine:

Side Effect Category	Examples (primarily associated with Alverine)
Gastrointestinal	Nausea, mild diarrhea, abdominal discomfort
Nervous System	Headache, dizziness
Allergic Reactions	Skin rash, itching, hives

If you experience dizziness, avoid driving or operating heavy machinery until you feel well.

Serious Side Effects (Very Rare)

Immediately stop taking the medicine and seek emergency medical attention if you experience signs of a severe allergic reaction, which may include:

Swelling of the face, lips, tongue, or throat
Difficulty breathing or wheezing
Severe dizziness or faintness

Also, seek urgent medical advice if you notice signs of a potential liver problem, such as:

Yellowing of the skin or the whites of the eyes (jaundice)
Unexplained, persistent nausea and vomiting
Unusual tiredness

Contraindications and Precautions

Do not take this medicine if you are allergic to alverine citrate, simethicone, or any of the inactive ingredients. It is also generally contraindicated if you have been diagnosed with:

Intestinal obstruction
Paralytic ileus (paralysis of the intestinal muscles)

Consult a healthcare professional before use if you are pregnant or breastfeeding, as safety data in these populations are limited. If symptoms worsen or do not improve after a few weeks of treatment, seek medical consultation to reassess the underlying condition.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Газоспазам (Simethicone) overexposure is strictly defined by the active ingredient's unique properties. Simethicone is a chemically inert substance that is not systemically absorbed following oral administration, meaning it does not enter the bloodstream to cause systemic toxic effects.

Documented Overdose Manifestations

Regulatory prescribing information confirms that no specific systemic clinical signs or symptoms of overdose are documented. This lack of absorption leads to the expectation that no severe or life-threatening outcomes affecting major physiological systems, such as neurological or cardiovascular systems, will be associated with Simethicone itself, and these effects are not reported in official labeling. Official documents do not define a dose level that results in specific toxic outcomes.

Mandated Emergency Actions and Management

Despite the absence of documented systemic toxicity, official government labeling mandates specific actions in the event of any suspected overexposure. It is a regulatory requirement to contact a poison control center right away or to seek immediate medical help for professional assessment. Due to the lack of systemic effects, management is described as symptomatic and supportive treatment, and no specific antidote is known or required. Furthermore, regulatory texts do not list population-specific considerations regarding increased toxicity in children or patients with organ impairment in this context.

Therapeutic Uses of Газоспазам

What Газоспазам Treats: Main Uses and Benefits

This medicine is commonly used to provide supportive symptomatic relief for conditions characterized by excessive gas accumulation and retention in the digestive tract. Specifically, it is used to address the discomfort associated with abdominal bloating, a feeling of uncomfortable fullness, and palpable pressure caused by trapped wind.

The use of this medicine is relevant across two main therapeutic areas: it helps ease physical manifestations for conditions like Irritable Bowel Syndrome (IBS) and is relevant for easing postoperative gas pain. Furthermore, a distinct clinical use is as an adjunct for diagnostic procedures, supporting examinations such as endoscopy and abdominal ultrasound. In these scenarios, the benefit is focused on helping to clear the visual field of foam and bubbles.

“The primary goal is easing physical distress by managing the symptoms of trapped or excessive gas.”

By managing symptoms related to gas, the medication may contribute to improved day-to-day comfort during episodes of heightened digestive distress and supports general well-being.

Quick Fact: Relief for Bloating
Primary Symptoms	Pressure, fullness, and abdominal distension
Clinical Contexts	Postoperative care, IBS-related gas, diagnostic preparation
Patient Benefit	Supports comfort and contributes to easing the overall symptom load

Regulatory References

NIH MedlinePlus Drug Information on Simethicone

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Газоспазам — official regulatory information

The official regulatory profile for Газоспазам (Simethicone) is defined by a single absolute contraindication and a broad eligibility scope across all ages, linked to its non-systemic action.

Eligibility Scope	Classification
Contraindicated Populations	Individuals with known hypersensitivity or allergy to Simethicone or any formulation component.
Age-Group Eligibility	Use is established and permitted across all age groups, including infants (under 2 years), children, adolescents, and older adults.
Pregnancy and Lactation Status	Use is permitted. Due to negligible systemic absorption, no effect is anticipated in pregnant or breastfeeding individuals.

Eligibility-related restrictions:

Gastrointestinal Integrity: Conditional use is required if a patient has a history of or suspected gastrointestinal obstruction or ileus.
Specific Use Not Recommended: The medicine is generally not recommended for the specific treatment of infant colic due to official evidence of limited efficacy.
Organ Function: No specific limitations are documented for patients with renal or hepatic impairment.

Connection to the overall eligibility profile: Regulatory documents confirm the medicine's non-systemic nature permits its use across nearly all patient populations. Eligibility limitations are strictly tied to allergic reactions or the need to avoid masking serious underlying gastrointestinal conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Газоспазам (Simeticone) is primarily structured by its pharmacological classification as a non-systemic agent. Official regulatory documentation confirms that Simeticone has negligible systemic absorption, which precludes the occurrence of traditional systemic drug–drug interactions.

Consequently, interactions mediated by metabolic pathways (such as CYP enzymes) or drug transporters are not documented in the official labeling, and no medicinal product combinations are formally classified as strictly contraindicated.

Exposure-Altering Interaction

The only clinically significant interaction noted in prescribing information is a local, physical phenomenon: co-administration with thyroid replacement hormones, specifically Levothyroxine, may decrease the oral bioavailability of the thyroid medication. This reduction in exposure is classified as a clinically significant, exposure-modifying interaction.

To manage this risk, regulatory authorities mandate a timing-based separation rule. Simeticone and thyroid replacement products must be administered at least 4 hours apart to mitigate the potential for physical interference with absorption.

Official documents do not specify any interaction-related restrictions concerning food, alcohol, or specific herbal products, nor do they detail population-specific interaction considerations (e.g., in hepatic impairment).

Mechanism of Action

The mechanism of action for Газоспазам (Simeticone) is based purely on a localized physicochemical action within the gastrointestinal tract.

Physicochemical Destabilization of Trapped Gas Foam

This domain covers the drug’s primary action: functioning as a surfactant to lower the surface tension of the small, stable gas bubbles in the gut lumen. This physical process initiates the rupture of the foam, which converts trapped gas to a mobile, free gas state.

Mechanistic Cascade of Coalescence and Mechanical Clearance

The immediate consequence of the surfactant action is the coalescence of the numerous small bubbles into larger, unstable pockets of free gas. This modification of gas dynamics supports the efficient mechanical clearance of gas, allowing it to be easily expelled via the body’s normal mechanisms, resulting in a reduction of mechanical pressure on the intestinal wall.

Non-Systemic Action and Boundaries of Effect

The drug is a chemically inert compound that is not absorbed into the bloodstream, confining its entire effect to the GI lumen. This mechanism involves non-modulation of systemic physiological systems, such as inflammation, motility, or neural pathways, confining its effect profile strictly to the physical modification of trapped foam.

Dosage and Administration Information

General Principles of Administration

The administration of Газоспазам (Simethicone) is strictly confined to the oral route, defining its use as a locally-acting agent within the gastrointestinal tract. The medication is generally taken on an as-needed (PRN) basis for symptom management.

Official Dosing and Frequency

The established usage pattern specifies that doses should be administered after meals and at bedtime for symptomatic relief. For adults and children 12 years of age and older, the typical single dose ranges from 40 mg to 250 mg. A critical instruction, especially for non-prescription use, is the maximum 24-hour limit, which must not exceed 500 mg.

Population-Specific Dosing

Official labels mandate specific adjustments for younger patients:

Age Group	Single Dose	Maximum Daily Dose
Children 2–12 years	40 mg	480 mg
Infants <2 years	20 mg	240 mg

Administration Requirements by Form

The method of physical intake is dependent on the dosage form to ensure proper action within the gut. Chewable tablets must be thoroughly chewed before swallowing. Conversely, liquid-filled capsules must be swallowed whole with water and should not be broken or chewed. If using the oral suspension or drops, the bottle must be shaken well, and the dose must be accurately measured, often using a dedicated dropper. The liquid may be mixed with water or other cool fluids, including infant formula, for easier administration.

Recent Clinical Evidence

Research evidence / Overview of studies for Газоспазам

Evidence for Use in Gas-Related Symptom Relief

The evidence for the use of Газоспазам (Simeticone) is drawn from short-term Randomized Controlled Trials (RCTs) and observational cohorts. This research explores how symptoms change over time in conditions characterized by fluctuating manifestations of gas discomfort, including functional bloating and symptoms associated with Irritable Bowel Syndrome (IBS). Studies examined patient-reported outcomes describing perceived discomfort related to physical metrics like abdominal distension.

Evidence for Use as an Adjunct in Diagnostic Procedures

The research base for this application is primarily derived from Systematic Reviews and Meta-analyses of numerous RCTs. Газоспазам was studied for its use prior to adults undergoing procedures like endoscopy and colonoscopy. Research examined outcomes related to the quality of mucosal visualization and the clearance of foam and bubbles, with the goal of evaluating changes in the endoscopist's visual field. Synthesized findings consistently reported measurements related to the clearance of foam.

Evidence for Use in Postoperative Gas Discomfort

Research exploring temporary physiological imbalance following surgery was evaluated in RCTs and retrospective observational studies in adult patients. Газоспазам was observed in research assessing outcomes describing episodic changes such as the remission rate of abdominal distension and the time to first flatus (passage of gas). Findings were mixed regarding the association of the agent with secondary outcomes, such as the duration of hospital stay, across various surgical contexts.

Research on Long-Term Outcomes and Follow-up

The available evidence describes the duration of outcomes that were measured during the study period, typically ranging from a few weeks for symptomatic uses. Long-term outcomes are not fully established, as there is limited information for long-term follow-up across the majority of the existing trials.

Evidence in Special Populations

Studies explored the use of Газоспазам in patient groups where symptoms may vary, particularly focusing on children and infants. Data for certain groups, such as older adults, remain insufficient. Research does not determine whether an individual will respond similarly across all age groups or comorbid conditions.

What is still uncertain about Газоспазам

There are areas where data are still emerging. The performance of the single-active ingredient can be uncertain, as a significant portion of the evidence is derived from studies where the agent was combined with other ingredients. Subgroup findings are uncertain, and research does not determine the certainty of whether reported changes in visualization during diagnostic procedures translate to a measurable long-term change in diagnostic accuracy. Research provides context but not individual predictions.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Газоспазам (FAQ)

Q: How quickly can a person expect to feel the effects of Газоспазам?

A: The medicine has two active components. The simethicone component, which targets gas bubbles, acts physically within the digestive tract and is not absorbed into the bloodstream. The other component, alverine citrate, is absorbed into the body, and its active form typically reaches its highest concentration approximately 1 to 1.5 hours after intake.

Q: Is it normal to feel a dry mouth while taking Газоспазам?

A: Dry mouth has been reported as an uncommon potential effect in regulatory documents for medicines containing this specific combination of ingredients. Concerns about side effects are typically addressed by a healthcare professional.

Q: Can Газоспазам cause drowsiness or affect concentration?

A: Official documentation notes that dizziness and somnolence (drowsiness) are potential effects. Official documentation indicates that dizziness may affect the ability to drive or operate heavy machinery.

Q: Are there any specific warning signs to look out for after starting Газоспазам?

A: Regulatory documents describe consulting a health professional if symptoms do not improve after two weeks of treatment or if new symptoms appear. Severe reactions such as difficulty breathing or swelling of the face, lips, tongue, or throat require immediate medical attention.

Q: Can I take Газоспазам if I have glaucoma?

A: Glaucoma is generally listed as a cautionary condition or contraindication for medicines in the anticholinergic class, which includes the active component alverine citrate. Regulatory information indicates that suitability for use must be determined by a health professional when conditions like glaucoma are present.

Q: Is it common for people to take Газоспазам only when symptoms appear, or is it usually scheduled?

A: Official administration guidelines state that the medicine is generally taken on an 'as-needed' basis for managing symptoms. The established usage pattern specifies that doses are administered after meals and at bedtime for symptomatic relief, rather than following a strict daily schedule.

Q: What does the evidence say about the typical duration of effect for Газоспазам?

A: The antiflatulent component, simethicone, is non-systemic and is typically administered as needed for short-term relief. The antispasmodic component reaches its highest concentration in the body about 1 to 1.5 hours after intake, which provides an indication of the onset of its effects.

Q: Is the component that targets gas different from the component that targets spasm?

A: Yes, the medicine contains two distinct active components. Simethicone is classified as an antiflatulent, acting locally within the gut to manage gas and foam. Alverine citrate is an antispasmodic, which acts as a spasmolytic agent to help reduce muscle spasms in the digestive tract.

Q: Is Газоспазам the same type of medicine as others often used for stomach discomfort?

A: Газоспазам is classified as an antispasmodic and antiflatulent. This is a specific class that targets muscle spasms and gas. It is chemically and functionally different from other common stomach medicines that primarily target stomach acid, such as antacids, PPIs, and H2-blockers.

Q: Does food affect the way Газоспазам works?

A: Official administration instructions specify taking the medicine after meals. This is a condition of use described in regulatory documentation to ensure proper administration.

Q: Is there a maximum period of time people typically use Газоспазам for?

A: Official patient information describes consulting a health professional if symptoms do not improve after two weeks of treatment. This is a general measure for duration of use and allows for reassessment of the condition.

Q: Does Газоспазам help with pain that is not related to muscle spasms?

A: The medicine is indicated for the symptomatic treatment of gastrointestinal disorders, including abdominal discomfort, pain, and cramps, which are associated with muscle spasms and trapped gas. Its primary mechanisms relate to relieving spasms and dispersing gas foam.

Q: Can Газоспазам be taken at the same time as other stomach-soothing medicines?

A: Regulatory documents state that interactions mediated by absorption into the bloodstream are not documented. The only local, physical interaction noted in official labeling is with thyroid hormones (Levothyroxine), which must be administered at least four hours apart.

Q: What do official documents say about driving or operating machinery while on Газоспазам?

A: Regulatory documents indicate that if a person experiences dizziness while taking the medicine, their ability to drive or operate heavy machinery may be impaired. This potential side effect should be considered.

Q: Can Газоспазам be crushed or dissolved?

A: This depends on the specific dosage form being used. Administration requirements state that liquid-filled capsules must be swallowed whole and must not be broken or crushed. Conversely, chewable tablets must be thoroughly chewed before swallowing.

Q: Is there a risk of withdrawal symptoms if I stop taking Газоспазам suddenly?

A: Regulatory information for similar formulations states the medicine is non-habit-forming. The medicine's pharmacological profile is not generally linked to rebound withdrawal symptoms.

Q: How long does Газоспазам stay in the body after the last dose?

A: The simethicone component is chemically inert, is not absorbed into the bloodstream, and is eliminated unchanged in the feces, meaning it acts locally. The other active component, alverine citrate, is rapidly metabolized and eliminated from the body shortly after absorption.

Q: Does the effectiveness of Газоспазам vary significantly among different people?

A: Regulatory summaries of available evidence state that research does not determine whether an individual will respond similarly across all age groups or comorbid conditions. Response can be influenced by various individual factors.

Q: Does the evidence suggest Газоспазам is effective for symptoms of irritable bowel syndrome (IBS)?

A: Research evidence indicates that the combination of active ingredients has been examined in studies of patients with Irritable Bowel Syndrome (IBS), reporting outcomes related to abdominal pain, discomfort, and bloating.

Q: Are there different brand names for the same active components as Газоспазам?

A: The combination of the two active ingredients, Simethicone and Alverine Citrate, may be available under different brand names in various regions globally. This is common for medicines with established active components.

How should Газоспазам be stored and disposed of?

How to Store and Dispose of Газоспазам

Official Storage Requirements

Condition	Regulatory Mandate
Temperature	Store below 25 C (Controlled Room Temperature).
Protection	Keep protected from both light and moisture.
Handling	The product must not be frozen.
Packaging	Keep the medicine in its original container until use.

Stability and Safety

Official labeling requires this medicine to be stored out of the sight and reach of children. The product should not be used past the expiration date printed on the packaging.

Disposal Rules

To ensure environmental safety, unused or expired Газоспазам must not be discarded in household trash or poured down a drain or toilet. Disposal should follow official guidelines, typically by returning the medicine to a designated pharmaceutical take-back program or pharmacy collection point, as defined by the regulatory documents.

Газоспазам